{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T06:23:34Z","timestamp":1781591014334,"version":"3.54.5"},"reference-count":94,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"vor","delay-in-days":2877,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1007\/s13311-015-0382-6","type":"journal-article","created":{"date-parts":[[2015,8,26]],"date-time":"2015-08-26T11:30:47Z","timestamp":1440588647000},"page":"816-824","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Cannabinoids and Schizophrenia: Risks and Therapeutic Potential"],"prefix":"10.1016","volume":"12","author":[{"given":"Marc W.","family":"Manseau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald C.","family":"Goff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-015-0382-6_bib1","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1001\/archpsyc.1996.01830110060007","article-title":"Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample. The National Comorbidity Survey","volume":"52","author":"Kendler","year":"1996","journal-title":"Arch Gen Psychiatry"},{"key":"10.1007\/s13311-015-0382-6_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.schres.2013.05.028","article-title":"Definition and description of schizophrenia in the DSM-5","volume":"150","author":"Tandon","year":"2013","journal-title":"Schizophr Res"},{"key":"10.1007\/s13311-015-0382-6_bib3","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.schres.2015.01.033","article-title":"A systematic review of the antipsychotic properties of cannabidiol in humans","volume":"162","author":"Iseger","year":"2015","journal-title":"Schizophr Res"},{"key":"10.1007\/s13311-015-0382-6_bib4","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3389\/fpsyt.2014.00054","article-title":"Gone to pot\u2014a review of the association between cannabis and psychosis","volume":"5","author":"Radhakrishnan","year":"2014","journal-title":"Front Psychiatry"},{"key":"10.1007\/s13311-015-0382-6_bib5","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1017\/S0033291713000433","article-title":"Change in cannabis use, clinical symptoms and social functioning among patients with first-episode psychosis: a 5-year follow-up study of patients in the OPUS trial","volume":"44","author":"Clausen","year":"2014","journal-title":"Psychol Med"},{"key":"10.1007\/s13311-015-0382-6_bib6","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S0140-6736(87)92620-1","article-title":"Cannibis and schizophrenia: A longitudinal study of Swedish conscripts","volume":"2","author":"Andreasson","year":"1987","journal-title":"Lancet"},{"key":"10.1007\/s13311-015-0382-6_bib7","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(07)61162-3","article-title":"Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review","volume":"370","author":"Moore","year":"2007","journal-title":"Lancet"},{"key":"10.1007\/s13311-015-0382-6_bib8","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1465-3362.2009.00132.x","article-title":"An overview of systematic reviews on cannabis and psychosis: discussing apparently conflicting results","volume":"29","author":"Minozzi","year":"2010","journal-title":"Drug Alcohol Rev"},{"key":"10.1007\/s13311-015-0382-6_bib9","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/0269881114564096","article-title":"Dementia praecox redux: A systematic review of the nicotinic receptor as a target for cognitive symptoms of schizophrenia","volume":"29","author":"Rowe","year":"2015","journal-title":"J Psychopharmacol"},{"key":"10.1007\/s13311-015-0382-6_bib10","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1038\/mp.2014.51","article-title":"Genetic predisposition to schizophrenia associated with increased use of cannabis","volume":"19","author":"Power","year":"2014","journal-title":"Mol Psychiatry"},{"key":"10.1007\/s13311-015-0382-6_bib11","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/archgenpsychiatry.2011.5","article-title":"Cannabis use and earlier onset of psychosis: a systematic meta-analysis","volume":"68","author":"Large","year":"2011","journal-title":"Arch Gen Psychiatry"},{"key":"10.1007\/s13311-015-0382-6_bib12","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.schres.2011.03.023","article-title":"Cannabis use disorder and age at onset of psychosis\u2013a study in first-episode patients","volume":"129","author":"Schimmelmann","year":"2011","journal-title":"Schizophr Res"},{"key":"10.1007\/s13311-015-0382-6_bib13","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/schbul\/sbs188","article-title":"Age at initiation of cannabis use predicts age at onset of psychosis: the 7- to 8-year trend","volume":"39","author":"Stefanis","year":"2013","journal-title":"Schizophr Bull"},{"key":"10.1007\/s13311-015-0382-6_bib14","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1360-0443.2011.03626.x","article-title":"Cannabis use and subclinical positive psychotic experiences in early adolescence: findings from a Dutch survey","volume":"107","author":"van Gastel","year":"2012","journal-title":"Addiction"},{"key":"10.1007\/s13311-015-0382-6_bib15","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.1360-0443.2005.01070.x","article-title":"Cannabis use predicts future psychotic symptoms, and vice versa","volume":"100","author":"Ferdinand","year":"2005","journal-title":"Addiction"},{"key":"10.1007\/s13311-015-0382-6_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmj.38267.664086.63","article-title":"Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people","volume":"330","author":"Henquet","year":"2005","journal-title":"BMJ"},{"key":"10.1007\/s13311-015-0382-6_bib17","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1001\/archgenpsychiatry.2010.6","article-title":"Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults","volume":"67","author":"McGrath","year":"2010","journal-title":"Arch Gen Psychiatry"},{"key":"10.1007\/s13311-015-0382-6_bib18","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S0140-6736(04)16200-4","article-title":"Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies","volume":"363","author":"Macleod","year":"2004","journal-title":"Lancet"},{"key":"10.1007\/s13311-015-0382-6_bib19","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3410\/M5-2","article-title":"Stronger evidence is needed before accepting that cannabis plays an important role in the aetiology of schizophrenia in the population","volume":"5","author":"Gage","year":"2013","journal-title":"F1000 Med Rep"},{"key":"10.1007\/s13311-015-0382-6_bib20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1017\/S0033291702006402","article-title":"Cannabis dependence and psychotic symptoms in young people","volume":"33","author":"Fergusson","year":"2003","journal-title":"Psychol Med"},{"key":"10.1007\/s13311-015-0382-6_bib21","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1017\/S0033291711002078","article-title":"Cannabis, schizophrenia and other non-affective psychoses: 35 years of follow-up of a population-based cohort","volume":"42","author":"Manrique-Garcia","year":"2012","journal-title":"Psychol Med"},{"key":"10.1007\/s13311-015-0382-6_bib22","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/j.2051-5545.2008.tb00158.x","article-title":"Cannabis use and the risk of developing a psychotic disorder","volume":"7","author":"Hall","year":"2008","journal-title":"World Psychiatry"},{"key":"10.1007\/s13311-015-0382-6_bib23","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1177\/070674370605100903","article-title":"Is cannabis a contributory cause of psychosis?","volume":"51","author":"Degenhardt","year":"2006","journal-title":"Can J Psychiatry"},{"key":"10.1007\/s13311-015-0382-6_bib24","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s00406-002-0366-5","article-title":"Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes","volume":"252","author":"Bersani","year":"2002","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1007\/s13311-015-0382-6_bib25","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1001\/archpsyc.65.11.1269","article-title":"Familial predisposition for psychiatric disorder: comparison of subjects treated for cannabis-induced psychosis and schizophrenia","volume":"65","author":"Arendt","year":"2008","journal-title":"Arch Gen Psychiatry"},{"key":"10.1007\/s13311-015-0382-6_bib26","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/acps.12108","article-title":"Psychosis-inducing effects of cannabis are related to both childhood abuse and COMT genotypes","volume":"129","author":"Alemany","year":"2014","journal-title":"Acta Psychiatr Scand"},{"key":"10.1007\/s13311-015-0382-6_bib27","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.schres.2013.07.020","article-title":"The effect of childhood maltreatment and cannabis use on adult psychotic symptoms is modified by the COMT Val(1)(5)(8)Met polymorphism","volume":"150","author":"Vinkers","year":"2013","journal-title":"Schizophr Res"},{"key":"10.1007\/s13311-015-0382-6_bib28","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1017\/S0033291711000973","article-title":"Replication in two independent population-based samples that childhood maltreatment and cannabis use synergistically impact on psychosis risk","volume":"42","author":"Konings","year":"2012","journal-title":"Psychol Med"},{"key":"10.1007\/s13311-015-0382-6_bib29","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1017\/S0033291711000559","article-title":"Cannabis use and psychosis: re-visiting the role of childhood trauma","volume":"41","author":"Houston","year":"2011","journal-title":"Psychol Med"},{"key":"10.1007\/s13311-015-0382-6_bib30","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1017\/S0033291709991966","article-title":"Cannabis use and childhood trauma interact additively to increase the risk of psychotic symptoms in adolescence","volume":"40","author":"Harley","year":"2010","journal-title":"Psychol Med"},{"key":"10.1007\/s13311-015-0382-6_bib31","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.drugalcdep.2004.05.005","article-title":"Preliminary evidence of an association between childhood abuse and cannabis dependence among African American first-episode schizophrenia-spectrum disorder patients","volume":"76","author":"Compton","year":"2004","journal-title":"Drug Alcohol Depend"},{"key":"10.1007\/s13311-015-0382-6_bib32","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1017\/S0033291711000511","article-title":"Do cannabis and urbanicity co-participate in causing psychosis? Evidence from a 10-year follow-up cohort study","volume":"41","author":"Kuepper","year":"2011","journal-title":"Psychol Med"},{"key":"10.1007\/s13311-015-0382-6_bib33","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/schbul\/sbq079","article-title":"The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample","volume":"38","author":"Yucel","year":"2012","journal-title":"Schizophr Bull"},{"key":"10.1007\/s13311-015-0382-6_bib34","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.schres.2010.10.005","article-title":"Pre-illness cannabis use and the early course of nonaffective psychotic disorders: associations with premorbid functioning, the prodrome, and mode of onset of psychosis","volume":"126","author":"Compton","year":"2011","journal-title":"Schizophr Res"},{"key":"10.1007\/s13311-015-0382-6_bib35","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.2174\/138161212802884672","article-title":"Cannabis use and duration of untreated psychosis: a systematic review and meta-analysis","volume":"18","author":"Burns","year":"2012","journal-title":"Curr Pharm Des"},{"key":"10.1007\/s13311-015-0382-6_bib36","first-page":"159","article-title":"The cannabis pathway to non-affective psychosis may reflect less neurobiological vulnerability","volume":"5","author":"Loberg","year":"2014","journal-title":"Front Psychiatry"},{"key":"10.1007\/s13311-015-0382-6_bib37","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.2174\/138161212802884753","article-title":"Neurological soft signs in patients with psychosis and cannabis abuse: a systematic review and meta-analysis of paradox","volume":"18","author":"Ruiz-Veguilla","year":"2012","journal-title":"Curr Pharm Des"},{"key":"10.1007\/s13311-015-0382-6_bib38","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/schbul\/sbu095","article-title":"The impact of cannabis use on clinical outcomes in recent onset psychosis","volume":"41","author":"Barrowclough","year":"2015","journal-title":"Schizophr Bull"},{"key":"10.1007\/s13311-015-0382-6_bib39","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1017\/S0033291713000883","article-title":"Cannabis use and first-episode psychosis: relationship with manic and psychotic symptoms, and with age at presentation","volume":"44","author":"Stone","year":"2014","journal-title":"Psychol Med"},{"key":"10.1007\/s13311-015-0382-6_bib40","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.2174\/138161212802884591","article-title":"Genetic variation underlying psychosis-inducing effects of cannabis: critical review and future directions","volume":"18","author":"Decoster","year":"2012","journal-title":"Curr Pharm Des"},{"key":"10.1007\/s13311-015-0382-6_bib41","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/ajmg.b.31174","article-title":"Age at onset of psychotic disorder: cannabis, BDNF Val66Met, and sex-specific models of gene-environment interaction","volume":"156B","author":"Decoster","year":"2011","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"10.1007\/s13311-015-0382-6_bib42","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/npp.2014.213","article-title":"Functional genetic variation of the cannabinoid receptor 1 and cannabis use interact on prefrontal connectivity and related working memory behavior","volume":"40","author":"Colizzi","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1007\/s13311-015-0382-6_bib43","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/ajmg.b.30592","article-title":"Cannabinoid receptor 1 gene (CNR1) and susceptibility to a quantitative phenotype for hebephrenic schizophrenia","volume":"147","author":"Chavarria-Siles","year":"2008","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"10.1007\/s13311-015-0382-6_bib44","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/sj.mp.4001029","article-title":"CNRI, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia","volume":"7","author":"Ujike","year":"2002","journal-title":"Mol Psychiatry"},{"key":"10.1007\/s13311-015-0382-6_bib45","first-page":"129","article-title":"The relationship between catechol-O-methyltransferase gene Val158Met (COMT) polymorphism and premorbid cannabis use in Turkish male patients with schizophrenia","volume":"29","author":"Ermis","year":"2015","journal-title":"In Vivo"},{"key":"10.1007\/s13311-015-0382-6_bib46","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1192\/bjp.bp.111.091421","article-title":"Cannabis, COMT and psychotic experiences","volume":"199","author":"Zammit","year":"2011","journal-title":"Br J Psychiatry"},{"key":"10.1007\/s13311-015-0382-6_bib47","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.biopsych.2012.06.020","article-title":"Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users","volume":"72","author":"Di Forti","year":"2012","journal-title":"Biol Psychiatry"},{"key":"10.1007\/s13311-015-0382-6_bib48","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1038\/npp.2011.141","article-title":"AKT1 moderation of cannabis-induced cognitive alterations in psychotic disorder","volume":"36","author":"van Winkel","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1007\/s13311-015-0382-6_bib49","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1586\/14737175.8.7.1037","article-title":"Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia","volume":"8","author":"Muller-Vahl","year":"2008","journal-title":"Expert Rev Neurother"},{"key":"10.1007\/s13311-015-0382-6_bib50","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/1574889809666140307115532","article-title":"Therapeutic potential of cannabinoids in schizophrenia","volume":"9","author":"Kucerova","year":"2014","journal-title":"Recent Pat CNS Drug Discov"},{"key":"10.1007\/s13311-015-0382-6_bib51","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1038\/npp.2013.165","article-title":"Peripheral endocannabinoid system dysregulation in first-episode psychosis","volume":"38","author":"Bioque","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1007\/s13311-015-0382-6_bib52","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3389\/fpsyt.2014.00118","article-title":"Endocannabinoid-dependent modulation of phasic dopamine signaling encodes external and internal reward-predictive cues","volume":"5","author":"Wenzel","year":"2014","journal-title":"Front Psychiatry"},{"key":"10.1007\/s13311-015-0382-6_bib53","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.2174\/092986710790980050","article-title":"Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists","volume":"17","author":"Pertwee","year":"2010","journal-title":"Curr Med Chem"},{"key":"10.1007\/s13311-015-0382-6_bib54","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1146\/annurev-clinpsy-032813-153631","article-title":"Epidemiological, neurobiological, and genetic clues to the mechanisms linking cannabis use to risk for nonaffective psychosis","volume":"10","author":"van Winkel","year":"2014","journal-title":"Annu Rev Clin Psychol"},{"key":"10.1007\/s13311-015-0382-6_bib55","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1523\/JNEUROSCI.3167-14.2015","article-title":"Cannabinoid CB1 receptor calibrates excitatory synaptic balance in the mouse hippocampus","volume":"35","author":"Monory","year":"2015","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-015-0382-6_bib56","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejphar.2015.03.063","article-title":"The interactive role of cannabinoid and vanilloid systems in hippocampal synaptic plasticity in rats","volume":"757","author":"Tahmasebi","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.1007\/s13311-015-0382-6_bib57","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.2174\/138161212802884843","article-title":"Anandamide dysfunction in prodromal and established psychosis","volume":"18","author":"Leweke","year":"2012","journal-title":"Curr Pharm Des"},{"key":"10.1007\/s13311-015-0382-6_bib58","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1192\/bjp.bp.108.053843","article-title":"Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis","volume":"194","author":"Koethe","year":"2009","journal-title":"Br J Psychiatry"},{"key":"10.1007\/s13311-015-0382-6_bib59","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1038\/sj.npp.1300558","article-title":"Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms","volume":"29","author":"Giuffrida","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1007\/s13311-015-0382-6_bib60","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1097\/00001756-199906030-00008","article-title":"Elevated endogenous cannabinoids in schizophrenia","volume":"10","author":"Leweke","year":"1999","journal-title":"Neuroreport"},{"key":"10.1007\/s13311-015-0382-6_bib61","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2007.04.025","article-title":"Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use","volume":"94","author":"Leweke","year":"2007","journal-title":"Schizophr Res"},{"key":"10.1007\/s13311-015-0382-6_bib62","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1192\/bjp.bp.112.121178","article-title":"Cerebrospinal fluid anandamide levels, cannabis use and psychotic-like symptoms","volume":"202","author":"Morgan","year":"2013","journal-title":"Br J Psychiatry"},{"key":"10.1007\/s13311-015-0382-6_bib63","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0006-8993(02)03055-X","article-title":"Delta(9)-tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: an in vivo microdialysis study","volume":"948","author":"Pistis","year":"2002","journal-title":"Brain Res"},{"key":"10.1007\/s13311-015-0382-6_bib64","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/sj.npp.1300496","article-title":"The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis","volume":"29","author":"D'Souza","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1007\/s13311-015-0382-6_bib65","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1017\/S0033291709005522","article-title":"The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning","volume":"39","author":"Morrison","year":"2009","journal-title":"Psychol Med"},{"key":"10.1007\/s13311-015-0382-6_bib66","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.biopsych.2004.12.006","article-title":"Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction","volume":"57","author":"D'Souza","year":"2005","journal-title":"Biol Psychiatry"},{"key":"10.1007\/s13311-015-0382-6_bib67","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1177\/0269881109358200","article-title":"Central nervous system effects of haloperidol on THC in healthy male volunteers","volume":"24","author":"Liem-Moolenaar","year":"2010","journal-title":"J Psychopharmacol"},{"key":"10.1007\/s13311-015-0382-6_bib68","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00213-007-1042-2","article-title":"Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Delta-9-tetrahydrocannabinol in humans","volume":"198","author":"D'Souza","year":"2008","journal-title":"Psychopharmacology"},{"key":"10.1007\/s13311-015-0382-6_bib69","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S2215-0366(14)00117-5","article-title":"Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study","volume":"2","author":"Di Forti","year":"2015","journal-title":"Lancet Psychiatry"},{"key":"10.1007\/s13311-015-0382-6_bib70","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1093\/schbul\/sbt181","article-title":"Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users","volume":"40","author":"Di Forti","year":"2014","journal-title":"Schizophr Bull"},{"key":"10.1007\/s13311-015-0382-6_bib71","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1177\/0269881114565142","article-title":"The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects","volume":"29","author":"van Amsterdam","year":"2015","journal-title":"J Psychopharmacol"},{"key":"10.1007\/s13311-015-0382-6_bib72","doi-asserted-by":"crossref","first-page":"4960","DOI":"10.2174\/138161212802884735","article-title":"Antipsychotic profile of cannabidiol and rimonabant in an animal model of emotional context processing in schizophrenia","volume":"18","author":"Levin","year":"2012","journal-title":"Curr Pharm Des"},{"key":"10.1007\/s13311-015-0382-6_bib73","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.2174\/138161212802884690","article-title":"Antipsychotic-like effects of cannabidiol and rimonabant: systematic review of animal and human studies","volume":"18","author":"Roser","year":"2012","journal-title":"Curr Pharm Des"},{"key":"10.1007\/s13311-015-0382-6_bib74","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/JCP.0b013e318204825b","article-title":"Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study","volume":"31","author":"Kelly","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"10.1007\/s13311-015-0382-6_bib75","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.schres.2011.11.009","article-title":"Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial","volume":"134","author":"Boggs","year":"2012","journal-title":"Schizophr Res"},{"key":"10.1007\/s13311-015-0382-6_bib76","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia","volume":"2","author":"Leweke","year":"2012","journal-title":"Transl Psychiatry"},{"key":"10.1007\/s13311-015-0382-6_bib77","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1002\/hipo.22339","article-title":"Differential regulation of NMDAR and NMDAR-mediated metaplasticity by anandamide and 2-AG in the hippocampus","volume":"24","author":"Yang","year":"2014","journal-title":"Hippocampus"},{"key":"10.1007\/s13311-015-0382-6_bib78","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1038\/nn.2684","article-title":"TRPV1 activation by endogenous anandamide triggers postsynaptic long-term depression in dentate gyrus","volume":"13","author":"Chavez","year":"2010","journal-title":"Nat Neurosci"},{"key":"10.1007\/s13311-015-0382-6_bib79","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.2174\/138161212802884780","article-title":"Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers","volume":"18","author":"Martin-Santos","year":"2012","journal-title":"Curr Pharm Des"},{"key":"10.1007\/s13311-015-0382-6_bib80","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/0269881112460109","article-title":"Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment","volume":"27","author":"Englund","year":"2013","journal-title":"J Psychopharmacol"},{"key":"10.1007\/s13311-015-0382-6_bib81","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/npp.2009.184","article-title":"Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology","volume":"35","author":"Bhattacharyya","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1007\/s13311-015-0382-6_bib82","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00213-011-2342-0","article-title":"Cannabidiol potentiates Delta(9)-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats","volume":"218","author":"Klein","year":"2011","journal-title":"Psychopharmacology"},{"key":"10.1007\/s13311-015-0382-6_bib83","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1017\/S0033291711001322","article-title":"Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being","volume":"42","author":"Morgan","year":"2012","journal-title":"Psychol Med"},{"key":"10.1007\/s13311-015-0382-6_bib84","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1192\/bjp.bp.107.046649","article-title":"Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis","volume":"192","author":"Morgan","year":"2008","journal-title":"Br J Psychiatry"},{"key":"10.1007\/s13311-015-0382-6_bib85","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.schres.2011.04.017","article-title":"Cannabis with high cannabidiol content is associated with fewer psychotic experiences","volume":"130","author":"Schubart","year":"2011","journal-title":"Schizophr Res"},{"key":"10.1007\/s13311-015-0382-6_bib86","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.biopsych.2006.08.027","article-title":"Dorsolateral prefrontal cortex N-acetylaspartate\/total creatine (NAA\/tCr) loss in male recreational cannabis users","volume":"61","author":"Hermann","year":"2007","journal-title":"Biol Psychiatry"},{"key":"10.1007\/s13311-015-0382-6_bib87","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.2174\/138161212802884825","article-title":"Potential protective effects of cannabidiol on neuroanatomical alterations in cannabis users and psychosis: a critical review","volume":"18","author":"Hermann","year":"2012","journal-title":"Curr Pharm Des"},{"key":"10.1007\/s13311-015-0382-6_bib88","first-page":"242","article-title":"Diminished gray matter in the hippocampus of cannabis users: possible protective effects of cannabidiol","volume":"114","author":"Demirakca","year":"2011","journal-title":"Drug Alcohol Depend"},{"key":"10.1007\/s13311-015-0382-6_bib89","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.euroneuro.2013.11.002","article-title":"Cannabidiol as a potential treatment for psychosis","volume":"24","author":"Schubart","year":"2014","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1007\/s13311-015-0382-6_bib90","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.schres.2015.01.015","article-title":"Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol","volume":"164","author":"Gomes","year":"2015","journal-title":"Schizophr Res"},{"key":"10.1007\/s13311-015-0382-6_bib91","first-page":"485","article-title":"Antipsychotic effect of cannabidiol","volume":"56","author":"Zuardi","year":"1995","journal-title":"J Clin Psychiatry"},{"key":"10.1007\/s13311-015-0382-6_bib92","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1177\/0269881106060967","article-title":"Cannabidiol monotherapy for treatment-resistant schizophrenia","volume":"20","author":"Zuardi","year":"2006","journal-title":"J Psychopharmacol"},{"key":"10.1007\/s13311-015-0382-6_bib93","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1177\/0269881108096519","article-title":"Cannabidiol for the treatment of psychosis in Parkinson's disease","volume":"23","author":"Zuardi","year":"2009","journal-title":"J Psychopharmacol"},{"key":"10.1007\/s13311-015-0382-6_bib94","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1590\/S1516-44462010000100011","article-title":"Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD)","volume":"31","author":"Hallak","year":"2010","journal-title":"Rev Bras Psiquiatr"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-015-0382-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-015-0382-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923008139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923008139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-015-0382-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:44:51Z","timestamp":1761806691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923008139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":94,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S1878747923008139"],"URL":"https:\/\/doi.org\/10.1007\/s13311-015-0382-6","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cannabinoids and Schizophrenia: Risks and Therapeutic Potential","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-015-0382-6","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}